Emla and Adriamycin pfs drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emla (lidocaine; prilocaine) and Adriamycin pfs (doxorubicin hydrochloride). Common drug interactions include abdominal distension among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Emla and Adriamycin pfs. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Emla?

Emla has active ingredients of lidocaine; prilocaine. eHealthMe is studying from 5,276 Emla users. Check the latest studies of Emla.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users. Check the latest studies of Adriamycin pfs.

On Jul, 09, 2026

25 people who take Emla and Adriamycin pfs together, and have interactions are studied.

Emla and Adriamycin pfs drug interactions.

What are the common drug interactions of Emla and Adriamycin Pfs, by gender? *:

female:

Abdominal distension
Abdominal pain upper
Actinic keratosis (skin disease due to sun exposure)
Adnexa uteri mass (ovarian cysts)
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Arteriosclerosis (thickening and hardening of arteries)
Arthropathy
Atelectasis (partial or complete collapse of the lung)

male:

Nausea (feeling of having an urge to vomit)
Abdominal distension
Ascites (accumulation of fluid in the abdominal cavity)
Atelectasis (partial or complete collapse of the lung)
Barrett's oesophagus (barrett's oesophagus is a disorder in which the lining of the oesophagus (the tube that carries food from the throat to the stomach) is damaged by stomach acid and changed to a lining similar to that of the stomach)
Bence jones protein urine present
Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
Cardiac arrest
Cardiomegaly (increased size of heart than normal)
Cellulitis (infection under the skin)

What are the common drug interactions of Emla and Adriamycin Pfs, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Anger
Anxiety
Attention deficit/hyperactivity disorder
Autism spectrum disorder (developmental disabilities that can cause significant social, communication and behavioural challenges)
B-cell lymphoma (blood cancer affecting b cells)
Bipolar disorder (mood disorder)
Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
Conjunctivitis (pink eye)
Cough
Depression

10-19:

n/a

20-29:

n/a

30-39:

Anaemia (lack of blood)
Dehydration (dryness resulting from the removal of water)
Febrile neutropenia (fever with reduced white blood cells)
Haemolytic anaemia (anaemia due to haemolysis)

40-49:

Neutropenia (an abnormally low number of neutrophils)
Oesophageal pain
Oral intake reduced
Dysphagia (a condition in which swallowing is difficult or painful)

50-59:

Abdominal discomfort
Abdominal distension
Arteriosclerosis (thickening and hardening of arteries)
Arthropathy
Asthenia (weakness)
Atelectasis (partial or complete collapse of the lung)
Back pain
Benign ovarian tumour
Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
Cervical spinal stenosis (narrowing of the spinal canal in the neck)

60+:

n/a

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 12 people, 48.00%
Multiple Myeloma (cancer of the plasma cells): 5 people, 20.00%
Pain: 4 people, 16.00%
Breast Cancer: 4 people, 16.00%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 3 people, 12.00%

* Approximation only. Some reports may have incomplete information.

Do you take Emla and Adriamycin pfs?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously